Articles

MacuSight has announced positive interim data from a Phase I study of its proprietary formulation of sirolimus (originally known as rapamycin) for the treatment of chronic, clinically significant diabetic macular oedema (DME).

Repeat injections of bevacizumab are well tolerated; Bevacizumab reduces DME in the short-term; Unveiling a new clinical entity; Pupil dilation linked to glaucoma progression; Glaucoma scales fail to impress; New glaucoma progression predictors; Central vision loss & trabeculectomy; UK optometrists given prescribing powers; Higher retinal re-attachment success in patients with complete PVD; Every other year screening for retinopathy; A new approach for analysing patient compliance.

If a sterile unit dose of cefuroxime were available it would become the world standard for endophthalmitis prophylaxis following the startling proof of its efficacy in the ESCRS endophthalmitis study last year. That was the conclusion of a debate for and against intracameral antibiotics at the JCRS Symposium, Controversies in Cataract & Refractive Surgery.

Persistent placoid maculopathy has features resembling macular serpiginous choroiditis but differs in its clinical course and effect on visual acuity.

Lower systolic perfusion pressure, lower systolic blood pressure and cardiovascular disease history are all predictors of glaucoma.

The desired refractive outcome is approximately 2 D by age two and 1 to 2 D by age three, reflecting the fact that the majority of growth of the eye has occurred by this age

I am sure many surgeons are familiar with these complaints and for those wishing to switch to bimanual cataract surgery, there are certainly a number of initial difficulties that must first be overcome.

In patients with open-angle glaucoma (OAG), the increase in intraocular pressure (IOP) caused by pharmacological pupillary dilation is related to the likelihood of future progression of glaucoma.

Repeat intravitreal injections of bevacizumab (off-label Avastin) for diseases such as proliferative diabetic retinopathy (DR), diabetic macular oedema (DME), retinal vein occlusions and choroidal neovascularization (CNV) appear to be safe and well tolerated.

I have been developing a new technology for the surgical treatment of myopia for some years now and I presented the results with my first set of patients at this year's ASCRS congress in San Diego, USA. Overall, I believe that this new, minimally invasive method of surgery could present a feasible alternative to invasive LASIK and intraocular surgery in moderate to high myopes.

Carl Zeiss to acquire Acri.Tec; B&L and Alcon settle dispute amicably; Alcon amends tender offer for Wavelight.

It's our birthday

Welcome to the October issue of OTE and the second anniversary edition of our magazine. Two years ago this month saw the first issue of OTE hit desks across Europe.

Bausch & Lomb and Alcon have settled a lawsuit that was filed recently regarding Alcon's promotional claims about Bausch & Lomb's ReNu MultiPlus solution.

Intravitreal bevacizumab can reduce diabetic macular oedema (DME) in some eyes, but a Phase III trial is required to determine whether the treatment is beneficial in the long-term.

The Visual Impairment Instrument (IVI) and the Glaucoma Symptom Scale (GSS) are suboptimal scales for assessing patients with glaucoma but relatively good vision.